Perspective Therapeutics Statistics
Want to see CATX full AI Analyst Report?
Perspective Therapeutics (CATX) Stock Statistics & Valuation Metrics
Total Valuation
Perspective Therapeutics has a market cap or net worth of $94.20M. The enterprise value is $134.04M.
- Market Cap
- $94.20M
- Enterprise Value
- $134.04M
Share Statistics
Perspective Therapeutics has 120,758,810 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 120,758,810
- Owned by Insiders
- 19.56%
- Owned by Institutions
- 54.10%
Financial Efficiency
Perspective Therapeutics’s return on equity (ROE) is -0.50 and return on invested capital (ROIC) is -47.16%.
- Return on Equity (ROE)
- -0.50
- Return on Assets (ROA)
- -0.39
- Return on Invested Capital (ROIC)
- -47.16%
- Return on Capital Employed (ROCE)
- -0.48
- Revenue Per Employee
- 0
- Profits Per Employee
- -624.98K
- Employee Count
- 165
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Perspective Therapeutics is -0.63. Perspective Therapeutics’s PEG ratio is -0.04.
- PE Ratio
- -0.63
- PS Ratio
- 532.23
- PB Ratio
- 0.32
- Price to FCF
- -0.68
- Price to Operating Cash Flow
- -0.87
- PEG Ratio
- -0.04
Income Statement
In the last 12 months, Perspective Therapeutics had revenue of 0 and earned -103.12M in profits. Earnings per share was -1.40.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -113.56M
- Pretax Income
- -104.43M
- Net Income
- -103.12M
- EBITDA
- -100.80M
- Earnings Per Share (EPS)
- -1.40
Cash Flow
In the last 12 months, operating cash flow was -108.13M and capital expenditures -30.66M, giving a free cash flow of -138.79M billion.
- Operating Cash Flow
- -108.13M
- Free Cash Flow
- -138.79M
- Free Cash Flow per Share
- -1.15
Dividends & Yields
Perspective Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -147.33%
- Earnings Yield
- -130.48%
Stock Price Statistics
- Beta
- 1.91
- 52-Week Price Change
- -65.79%
- 50-Day Moving Average
- 2.06
- 200-Day Moving Average
- 3.41
- Relative Strength Index (RSI)
- 27.58
- Average Volume (3m)
- 2.69M
Important Dates
Perspective Therapeutics upcoming earnings date is Apr 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 09, 2026
- Next Earnings Date
- Apr 01, 2027
- Ex-Dividend Date
- ―
Financial Position
Perspective Therapeutics as a current ratio of 5.17, with Debt / Equity ratio of 1.57%
- Current Ratio
- 5.17
- Quick Ratio
- 5.17
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- 0.27
- Interest Coverage Ratio
- -302.03
Taxes
In the past 12 months, Perspective Therapeutics has paid -793.00K in taxes.
- Income Tax
- -793.00K
- Effective Tax Rate
- 0.01
Enterprise Valuation
Perspective Therapeutics EV to EBITDA ratio is -0.47, with an EV/FCF ratio of -0.41.
- EV to Sales
- 320.81
- EV to EBITDA
- -0.47
- EV to Free Cash Flow
- -0.41
- EV to Operating Cash Flow
- -0.53
Balance Sheet
Perspective Therapeutics has $201.69M in cash and marketable securities with $3.62M in debt, giving a net cash position of $198.07M billion.
- Cash & Marketable Securities
- $201.69M
- Total Debt
- $3.62M
- Net Cash
- $198.07M
- Net Cash Per Share
- $1.64
- Tangible Book Value Per Share
- $2.11
Margins
Gross margin is -536.16%, with operating margin of -74402.82%, and net profit margin of -69438.98%.
- Gross Margin
- -536.16%
- Operating Margin
- -74402.82%
- Pretax Margin
- -69887.57%
- Net Profit Margin
- -69438.98%
- EBITDA Margin
- -68378.53%
- EBIT Margin
- -70904.52%
Analyst Forecast
The average price target for Perspective Therapeutics is $7.89, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $7.89
- Price Target Upside
- 911.40% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 10
- Revenue Growth Forecast
- -79.53%
- EPS Growth Forecast
- 14.45%
Scores
- Smart Score
- 5
- AI Score
- 47

